诺和诺德(NVO.US)斥资最高21亿美元携手Vivtex，加码下一代口服减肥药

Core Viewpoint - Danish pharmaceutical company Novo Nordisk (NVO.US) has entered into a collaboration agreement with US-based Vivtex, valued at up to $2.1 billion, to jointly develop next-generation oral medications for obesity and diabetes [1][2] Group 1: Collaboration Details - The agreement includes an undisclosed upfront payment, milestone payments, and royalties on future product sales [2] - Vivtex will license part of its oral drug delivery technology, while Novo Nordisk will handle global development and commercialization [1] Group 2: Technology and Innovation - The collaboration leverages Vivtex's disruptive oral delivery research platform, developed with contributions from renowned MIT scientist and Moderna co-founder Robert Langer [1] - The platform integrates advanced gastrointestinal chip models, high-throughput automated screening, and AI predictive algorithms to enhance drug absorption in the human gut [1] Group 3: Market Context - Novo Nordisk currently offers GLP-1 medications for obesity and type 2 diabetes, including Wegovy, Ozempic, and the oral diabetes medication Rybelsus [2] - In January, Novo Nordisk launched Wegovy tablets in the US, marking the world's first oral medication for obesity treatment [2]